Sugi Predict

Sugi Predict / Compounds / SCHEMBL18865880

SCHEMBL18865880

SCHEMBL18865880

NCCC1CCN(c2cccnc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.58
▸ DRD2 P14416 1/20 0.51
▸ DRD3 P35462 1/20 0.51
▸ DPP4 P27487 1/20 0.49
▸ DPP8 Q6V1X1 1/20 0.49
▸ DPP9 Q86TI2 1/20 0.49
▸ DPP7 Q9UHL4 1/20 0.49
▸ CHRNB2 P17787 6/20 0.49
▸ CHRNA4 P43681 6/20 0.49
▸ CHRNB4 P30926 3/20 0.49
▸ CHRNA3 P32297 3/20 0.49
▸ GPR119 Q8TDV5 1/20 0.47
▸ ROCK2 O75116 1/20 0.46
▸ ROCK1 Q13464 1/20 0.46
▸ CDC42BPB Q9Y5S2 1/20 0.46
▸ CHRNA1 P02708 1/20 0.44
▸ CHRNG P07510 1/20 0.44
▸ CHRNB1 P11230 1/20 0.44
▸ CHRNA7 P36544 1/20 0.44
▸ CHRND Q07001 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29691060 1.00 HRH3 (0.58) HRH3DRD2DRD3DPP4DPP8
SCHEMBL29691048 0.88 HRH3 (0.60) HRH3DRD2DRD3DPP4DPP8
SCHEMBL18865837 0.88 HRH3 (0.60) HRH3DRD2DRD3DPP4DPP8
SCHEMBL26627810 0.83 HRH3 (0.62) HRH3DRD2DRD3CHRNB2CHRNA4
SCHEMBL30462025 0.83 HRH3 (0.62) HRH3DRD2DRD3CHRNB2CHRNA4
SCHEMBL24671758 0.81 HRH3 (0.60) HRH3DRD2DRD3DPP4DPP8
SCHEMBL30066472 0.81 HRH3 (0.60) HRH3DRD2DRD3DPP4DPP8
SCHEMBL12377900 0.81 HRH3 (0.60) HRH3DRD2DRD3DPP4DPP8
SCHEMBL785766 0.81 CHKA (0.50) HRH3DRD2DRD3DPP4DPP8
SCHEMBL4703341 0.80 CYP2D6 (0.50) HRH3DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2022-09-08 — — US disclosed
CN-114702495-A Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-07-05 — — CN disclosed
CN-108473495-B Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-04-12 — — CN disclosed
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
EP-3696181-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2020-08-19 — — EP disclosed
EP-3696181-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2020-08-19 — — EP disclosed
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-03 — — US disclosed
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-03 — — US disclosed
EP-2688568-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-06-19 — — EP disclosed
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-29 — — US disclosed
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-29 — — US disclosed
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2018-11-29 — — US disclosed
EP-3377493-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2018-09-26 — — EP disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 HRH3 1870/4885DRD2 3351/4885DRD3 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.